A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade

Liver International

Volumn 26, Issue 6, 2006, Pages 726-733

  Di Stefano, Giuseppina ^a   Fiume, Luigi ^a   Baglioni, Michele ^a   Bolondi, Luigi ^a,b   Busi, Corrado ^a   Chieco, Pasquale ^b   Kratz, Felix ^c   Manaresi, Francesca ^a   Pariali, Milena ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Drug targeting; Hepatocellular carcinoma chemotherapy; Hepatocellular carcinoma targeted doxorubicin; Lactosaminated human albumin

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; DIETHYLNITROSAMINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DOXORUBICIN LACTOSAMINATED HUMAN SERUM ALBUMIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; HISTOPATHOLOGY; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NONHUMAN; RAT; TUMOR DIFFERENTIATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIFFERENTIATION; DOXORUBICIN; HUMANS; LEUKOCYTE COUNT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 33745589227     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01289.x     Document Type: Article

References (31)

1. Hyodo I, Mizuno M, Yamada G, Tsuji T. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 1993; 13: 80-5.
2. TrerÈD, Fiume L, Badiali de G L, et al. The asialoglycoprotein receptor in human hepatocellular carcinomas: Its expression on proliferating cells. Br J Cancer 1999; 81: 404-8.
3. Di Stefano G, Kratz F, Lanza M, Fiume L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig Liver Dis 2003; 35: 428-33.
4. Morell A G, Irvine R A, Sternlieb I, Scheinberg I H, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 1968; 243: 155-9.
5. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-4.
6. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J Biol Chem 1978; 253: 2070-2.
7. Fiume L, Busi C, Mattioli A, Barbanti-Brodano G. Hepatocyte targeting of adenine-9-β- d -arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 1981; 129: 261-4.
8. Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β- d -arabinofuranosyladenine 5′-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986; 35: 967-72.
9. Fiume L, Bonino F, Mattioli A, et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988; 2: 13-5.
10. Torrani Cerenzia M R, Fiume L, De Bernardi Venon W, et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects. Hepatology 1996; 23: 657-61.
11. Zarski J P, Barange K, Souvignet C, et al. Efficacy and safety of L-HSA-ara-AMP in chronic hepatitis B patients non responder to interferon therapy: A randomised clinical trial. J Hepatol 2001; 34: 487-8.
12. Willner D, Trail P A, Hofstead S J, et al. 6-Maleimidocaproyl)hydrazone derivative of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem 1993; 4: 521-7.
13. Greenfield R S, Kaneko T, Daues A, et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 1990; 50: 6600-7.
14. Fiume L, Bolondi L, Busi C, et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol 2005; 43: 645-52.
15. Di Stefano G, Fiume L, Bolondi L, Lanza M, Pariali M, Chieco P. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumours. Liver Int 2005; 25: 854-60.
16. Schwartz B A, Gray G R. Proteins containing reductively aminated saccharides. Synthesis and chemical characterization. Arch Biochem Biophys 1977; 181: 542-9.
17. Kratz F, Warnecke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol binding doxorubicin derivatives: Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to the parent compound. J Med Chem 2002; 45: 5523-33.
18. Di Stefano G, Lanza M, Kratz F, Merina L, Fiume L. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: Synthesis, characterization and preliminary biological properties of the conjugate. Eur J Pharm Sci 2004; 23: 393-97.
19. Lowry O H, Rosebrough N J, Farr A L, Randall L J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
20. Pittman R C, Green S R, Attie A D, Steinberg D. Radiolabeled sucrose covalently linked to protein. A device for quantifying degradation of plasma proteins catabolized by lysosomal mechanisms. J Biol Chem 1979; 254: 6876-9.
21. Rajewsky M F, Dauber W, Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 1966; 152: 83-5.
22. Bots A M, Van Oort W J, Noordoek J, Van Dijk A, Klein S W, Van Hoesel Q G. Analysis of adriamycin and adriamycinol in micro volumes of rat plasma. J Chromatogr 1983; 272: 421-7.
23. Wall D A, Maack T. Endocytic uptake, transport and catabolism of proteins by epithelial cells. Am J Physiol 1985; Cell Physiol 248(17): C12-20.
24. Mukherjee S, Grosh R N, Maxfield F R. Endocytosis. Physiol Rev 1997; 77: 759-803.
25. Kratz F, Beyer U, Schütte M T. Drug-Polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst 1999; 16: 245-88.
26. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert J M. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 1980; 597: 1-14.
27. Tritton T R. Cell surface actions of adriamycin. Pharm Ther 1991; 49: 293-309.
28. Van der Sluijs P, Meijer D K. Limitation on the specificity of targeting asialoglycoprotein-drug conjugates to hepatocytes. In: Wu Y J, Wu C H, eds. Liver Diseases. Targeted Diagnosis and Therapy Using Specific Receptors and Ligands. New York: Marcel Dekker, 1991; 235-64.
29. Di Stefano G, Derenzini M, Kratz F, Lanza M, Fiume L. Liver targeted doxorubicin: Effects on regenerating rat hepatocytes. Liver Int 2004; 24: 246-52.
30. Di Stefano G, Fiume L, Domenicali M, et al. Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis. Dig Liver Dis 2006, doi: 10.1016/j.dld.2006.02.010.
31. Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.